Evidence map›Paper›PMID 30920627›Full record

ArticleThe Journal of clinical endocrinology and metabolism2019

Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients.

Yasunori Suematsu, Masaki Goto, Christina Park, Ane C F Nunes, WangHui Jing, Elani Streja, Connie M Rhee, Siobanth Cruz, Moti L Kashyap, Nosratola D Vaziri and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Yasunori SuematsuDivision of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California.
Masaki GotoDivision of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California.
Christina ParkDivision of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California.
Ane C F NunesDivision of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California.
WangHui JingDivision of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California.
Elani StrejaDivision of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California.
Connie M RheeDivision of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California.
Siobanth CruzDepartment of Chemistry & Biochemistry, California State University Long Beach, Long Beach, California.
Moti L KashyapAtherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, California.
Nosratola D VaziriDivision of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California.
Vasanthy NarayanaswamiDepartment of Chemistry & Biochemistry, California State University Long Beach, Long Beach, California.
Kamyar Kalantar-ZadehDivision of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California.
Hamid MoradiDivision of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California.
University of California, Irvine · USCalifornia State University, Long Beach · US

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Transendothelial transport mediated modulations to the High Density LipoproteinSC3GM105561 · NIGMS · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI NARAYANASWAMI, VASANTHY · 2013 to 2021
$876k
HDL function and mortality in end stage renal diseaseIK2CX001043 · VA · VETERANS HEALTH ADMINISTRATION · PI MORADI, HAMID · 2015 to 2020
–
CSRD VA IK2 CX001043NCATS NIH HHS UL1 TR001414NIGMS NIH HHS SC3 GM105561
6 · The paper itself

Abstract

contextIn end-stage renal disease (ESRD), serum high-density lipoprotein cholesterol (HDL-C) level is not an accurate predictor of mortality, partly because it does not necessarily correlate with indices of HDL function. Paraoxonase (PON) is a major enzyme constituent of HDL and a key component of HDL antioxidant activity. Apolipoprotein A-I (Apo A-1) is the core HDL structural protein that plays a major role in various aspects of HDL function.

objectiveWe sought to examine PON activity and Apo A-I levels in patients with ESRD vs healthy controls. DESIGN AND

settingPON/arylesterase activity was measured in 499 patients with maintenance hemodialysis (MHD) and 24 healthy controls with similar distributions of age, sex, and race/ethnicity. Serum acrolein-modified Apo A-I was measured in 30 patients with MHD and 10 healthy controls.

main outcome measuresMultilevel Cox models were used to assess associations among PON activity, Apo A-I, and HDL-C levels with 12-month all-cause mortality.

resultsPON activity was significantly lower in patients with MHD vs controls. Furthermore, acrolein-modified Apo A-I levels were higher in patients with MHD vs controls. In fully adjusted models, high PON activity was associated with lower 12-month mortality, whereas no difference of mortality risk was observed across HDL-C levels. The combination of high PON and low Apo A-I compared with low PON and low Apo A-I was associated with lower mortality risk.

conclusionsIn patients with MHD, PON activity had a stronger association with 12-month mortality than HDL-C. Future studies are needed to examine the role of these markers as potential diagnostic and therapeutic tools in ESRD.

Indexed as

Kidney Failure, ChronicRenal DialysisAdultAgedApolipoprotein A-IAryldialkylphosphataseBiomarkersCarboxylic Ester HydrolasesCase-Control StudiesCause of DeathCholesterol, HDLCohort StudiesFemaleHumansMaleMiddle AgedAPOA1 protein, humanApolipoprotein A-IAryldialkylphosphatasearylesteraseBiomarkersCarboxylic Ester HydrolasesCholesterol, HDL

Identifiers

PMID30920627
PMCPMC6733492
OpenAlexW2933143332

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.